Post hoc analysis of the CANTOS trial suggested that IL-1β inhibition may improve heart failure outcomes after myocardial infarction,48 although such analyses can only be seen as hypothesis generating, rather than informing clinical practice. This evidence concerns the gene IL1B and myocardial infarction.